Investor Presentaiton

SELECT TRIALS - RETATRUTIDE Lilly Study Indication* Title Phase Patients Primary Outcome* ** Primary Completion Completion Chronic NCT05936151 Kidney Disease A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes 2 120 Change from Baseline in Glomerular Filtration Rate (GFR) Feb 2025 Feb 2025 NCT05931367 Obesity A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4) 3 405 Percent Change from Baseline in Body Weight and Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score Oct 2025 Nov 2025 NCT05882045 Obesity A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) 3 1800 Percent Change from Baseline in Body Weight Nov 2025 Dec 2025 NCT05929066 Obesity A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) 3 2100 Percent Change From Baseline in Body Weight Apr 2026 May 2026 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Obesity Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) 3 1000 Percent Change from Baseline in Body Weight May 2026 May 2026 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Source: clinicaltrials.gov, July 18, 2023 46 2023 Q2 EARNINGS 40

View entire presentation